Questions over efficacy, blood-clot fears, threats to block exports and sluggish supply - the distribution of vaccines has been causing major division across Europe, particularly between the EU and the UK. The European Commission President Ursula von der Leyen has said AstraZeneca must honour its contract with the bloc before exporting vaccines out of the EU – a move which could significantly impact the UK’s vaccine supply.
So with that in mind, on The Agenda this week Stephen Cole is joined by a panel of guests to discuss the potential pitfalls of prioritising competition over cooperation, and how the disputes of today could affect the vaccine procurement of tomorrow and beyond.
France and Germany have both witnessed vaccine hesitation within their populations. We ask Pieter Cleppe, Editor-in-chief of Brussels Report, about why that might be, as well as whether Brexit is to blame for a seemingly cold reception towards the UK’s AstraZeneca jab.
How do the EU and UK vaccine rollout strategies compare? Are there more concerns about the UK-made AstraZeneca jab than other COVID-19 vaccines? And how damaging is vaccine nationalism? We find out from Professor Lawrence Young, virologist & specialist in molecular oncology at the University of Warwick.
Also joining the discussion is David Henig, Director of the UK Trade Policy Project who explains what he thinks the EU must do to emerge from the vaccine setback with strength and stability going forward.
Watch #TheAgenda in full and find out more at: https://www.cgtn.com/europe/the-agenda 📲
Follow CGTN Europe on social media and other platforms👇🏼